The Uncertain Impact Cannabis Has on COVID-19 Highlights Need for Rescheduling

The Schedule I status of marijuana stunts America’s ability to contribute to worldwide cannabis research. In light of the recent COVID-19 pandemic, these limitations became that much more apparent. 

Today, much of the world remains in the dark when it comes to understanding cannabis, according to Dr. Laszlo Mechtler, Medical Director of the Dent Neurological Institute in Buffalo, NY. Dr. Mechtler told High Times that most people, at best, have a rudimentary understanding of the plant and its benefits. 

The medical professional, whose roles include chief of neuro-oncology at the Roswell Park Center Institute, credits media outlets like High Times for disseminating information. However, he said that a lack of research prohibits a robust flow of information to the public.

”It is my opinion that much of this lack of understanding stems from the lack of research that has been done on cannabis, which is rooted in marijuana’s classification as a Schedule I controlled substance by the federal government,” said Dr. Mechtler. 

The Impact of Marijuana’s Schedule I Classification

The doctor’s sentiment is shared by much of the cannabis community, and those seeking to legitimize a burgeoning industry and medication further. 

Dr. Nimesh Patel, a co-founder of Redbird Bioscience, delved into the limitations created by marijuana’s Schedule I status. “The schedule 1 status is what keeps the plant from being studied by numerous scientific centers and conducting numerous…

Original Author Link click here to read complete story..

Latest posts